N/A
N=100
Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in TAP Blocks
Pregnancy
Bottom Line
View on ClinicalTrials.gov: NCT02472522 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcome: Primary: The Time After the TAP Block When Rescue Analgesia Was First Sought — 13.12; 18.21 Hours
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ropivacaine + Dexmedetomidine (Drug); Ropivacaine (Other)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Tata Main Hospital
- Primary completion
- Nov 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Time After the TAP Block When Rescue Analgesia Was First Sought |
13.12; 18.21 | — |
| SECONDARY Total Dose of Required Morphine in 24 Hours Postoperatively |
8.16; 6.21 | — |
| SECONDARY Adverse Effects Like Pruritus, Nausea and Vomiting |
1; 0; 2; 1; 47; 49 | — |
Summary
Comparative study of Ropivacaine and Ropivacaine with dexmedetomidine in transversus abdominis plane (TAP) block for post-operative analgesia in patients undergoing Caesarean Section.
Eligibility Criteria
Inclusion Criteria
- ASA 1 or 2
- Age above 18 years
- Patients for Lower Section Cesarean Section surgery
Exclusion Criteria
- Patient refusal
- Allergy to study medications
- Localized infection over injection point
- Patients with significant coagulopathies and with contraindications to regional anesthesia
- Patients with a history of cardiac, respiratory, renal or hepatic failure
- Psychological disorders
- Chronic use of pain medications or adrenoreceptors agonists or antagonists.
- BMI >35 or weight < 50 kilograms
Data sourced from ClinicalTrials.gov (NCT02472522). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.